No abstract

No abstract

Conflicts of Interest and Source of FundingMF received speakers' honoraria and support for travel to meetings from Bristol-Myers Squibb (BMS), Gilead, Janssen-Cilag, Merck Sharp & Dohme (MSD), ViiV Healtcare, and fees for attending advisory boards from BMS, Gilead and Janssen-Cilag. AB received speaker's honoraria from Janssen-Cilag and fees for attending an advisory board from Viiv Healthcare. NS received a grant for advisor from ViiV and travel grants and speaker's honoraria from Gilead and Janssen. MC declares personal fees from Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme, ViiV Healthcare, and Bristol-Myers Squibb, outside the submitted work. LT received fees for attending advisory boards from Janssen-Cilag and ViiV Healtcare and support for travel to meetings from Gilead, Janssen-Cilag, Merck Sharp & Dohme (MSD). BR received speakers' honoraria and support for travel to meetings from Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme (MSD), ViiV Healthcare, and fees for attending advisory boards from ViiV Healthcare, Janssen-Cilag, Merck Sharp & Dohme (MSD), Gilead Sciences, Bristol-Myers Squibb (BMS). AC received travel grants from ViiV Healthcare. ADB received speakers' honoraria and support for travel to meetings